A Phase 1, Open-Label 3 Sequence 3 Period Crossover Study Of Palbociclib (PD-0332991) In Healthy Volunteers To Establish The Bioequivalence Of The Phase 1/2 And Phase 3 Formulation To Palbociclib ICH Formulation Under Fasted Conditions
Phase of Trial: Phase I
Latest Information Update: 17 Jan 2014
Price : $35 *
At a glance
- Drugs Palbociclib (Primary)
- Indications Breast cancer; Colorectal cancer; Glioblastoma; Liposarcoma; Mantle-cell lymphoma; Multiple myeloma; Solid tumours
- Focus Pharmacokinetics
- Sponsors Pfizer
- 17 Jan 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 02 Dec 2013 Planned number of patients changed from 60 to 73 as reported by ClinicalTrials.gov.
- 02 Dec 2013 Planned End Date changed from 1 Nov 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.